Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Sponsor: Incyte Corporation
Summary
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Official title: A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
710
Start Date
2024-01-04
Completion Date
2027-01-01
Last Updated
2026-03-16
Healthy Volunteers
No
Conditions
Interventions
INCB161734
INCB161734 will be administered at protocol defined dose.
Cetuximab
Cetuximab will be administered at protocol defined dose.
Retifanlimab
Retifanlimab will be administered at protocol defined dose.
GEMNabP
GEMNabP will be administered at protocol defined dose.
mFOLFIRINOX
mFOLFIRINOX will be administered at protocol defined dose.
FOLFOX
FOLFOX will be administered at protocol defined dose.
FOLFIRI
FOLFIRI will be administered at protocol defined dose.
INCA33890
INCA33890 will be administered at protocol defined dose.
Locations (34)
Mayo Clinic Hospital
Phoenix, Arizona, United States
Stanford University
Palo Alto, California, United States
UCLA Healthcare Hematology-Oncology
Santa Monica, California, United States
Sarah Cannon Research Institue At Healthone
Denver, Colorado, United States
Florida Cancer Specialists
Sarasota, Florida, United States
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
Baltimore, Maryland, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Weill Cornell Medicine
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Jefferson University Hospitals
Philadelphia, Pennsylvania, United States
Scri Oncology Partners
Nashville, Tennessee, United States
Md Anderson Cancer Center
Houston, Texas, United States
Chris Obrien Lifehouse
Camperdown, New South Wales, Australia
St Vincent'S Hospital Sydney
Darlinghurst, New South Wales, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Peter Maccallum Cancer Centre
North Melbourne, Victoria, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
Cliniques Universitaires Ucl Saint-Luc
Brussels, Belgium
Universitair Ziekenhuis Antwerpen (Uza)
Edegem, Belgium
Universitair Ziekenhuis (Uz) Leuven
Leuven, Belgium
The Ottawa Hospital Cancer Center
Ottawa, Ontario, Canada
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Centre Leon Berard
Lyon, France
Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole
Toulouse, France
Institut Gustave Roussy
Villejuif, France
Fondazione Irccs Istituto Nazionale Dei Tumori
Milan, Italy
Irccs Istituto Clinico Humanitas
Rozzano, Italy
Centro Ricerche Cliniche Di Verona
Verona, Italy
National Cancer Center Hospital East
Chiba, Japan
The Cancer Institute Hospital of Jfcr
Tokyo, Japan
Hospital General Universitario Vall D Hebron
Barcelona, Spain
Fundacion Jimenez Diaz
Madrid, Spain
Hospital Universitario Quironsalud Madrid
Madrid, Spain